Search research articles
Contact Us
Filters
Showing results (691-700 of 721) with videos related to
Page
of 73
Sort By:
The Lancet. Haematology
|
May 4, 2023
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
Cristina Nanni, Carsten Kobe, Bettina Baeßler, et al.
The Lancet. Oncology
|
August 7, 2025
[<sup>68</sup>Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Kim M Pabst, Manuel M Weber, Christina Laschinsky, et al.
European Urology Oncology
|
April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study
Ronan Flippot, Tugce Telli, Maud Velev, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 19, 2026
Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy
Conrad-Amadeus Voltin, Sarah Flossdorf, Lars Kurch, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 15, 2025
The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 <sup>68</sup>Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management
Frederik L Giesel, Stefan A Koerber, Boris Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 10, 2019
Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma
Cristina Ferrone, Lipika Goyal, Motaz Qadan, et al.
European Urology
|
September 24, 2023
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer
Daniela-Elena Oprea-Lager, Steven MacLennan, Anders Bjartell, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 2, 2016
[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity
Woosuk Kim, Thuc M Le, Liu Wei, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
European Urology
|
September 13, 2025
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis
Ken Herrmann, Jochen Walz, Steven MacLennan, et al.
Page
of 73
Search research articles
Search
Showing results (691-700 of 721) with videos related to
Sort By:
Page
of 73
The Lancet. Haematology
|
May 4, 2023
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
Cristina Nanni, Carsten Kobe, Bettina Baeßler, et al.
The Lancet. Oncology
|
August 7, 2025
[<sup>68</sup>Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Kim M Pabst, Manuel M Weber, Christina Laschinsky, et al.
European Urology Oncology
|
April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study
Ronan Flippot, Tugce Telli, Maud Velev, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 19, 2026
Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy
Conrad-Amadeus Voltin, Sarah Flossdorf, Lars Kurch, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 15, 2025
The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 <sup>68</sup>Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management
Frederik L Giesel, Stefan A Koerber, Boris Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 10, 2019
Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma
Cristina Ferrone, Lipika Goyal, Motaz Qadan, et al.
European Urology
|
September 24, 2023
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer
Daniela-Elena Oprea-Lager, Steven MacLennan, Anders Bjartell, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 2, 2016
[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity
Woosuk Kim, Thuc M Le, Liu Wei, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
European Urology
|
September 13, 2025
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis
Ken Herrmann, Jochen Walz, Steven MacLennan, et al.
Page
of 73